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Abstract
OBJECTIVE: To evaluate the efficacy of Jianpi thera-
py in Traditional Chinese Medicine (TCM) for treat-
ment of chronic obstructive pulmonary disease
(COPD) in stable phase by performing a systematic
review and meta-analysis.
METHODS: The literatures concerning randomized
controlled trials (RCTs) and quasi-RCTs comparing
TCM treatment plus Western Medicine (WM) treat-
ment with TCM alone, or TCM treatment vs no treat-
ment, placebo for stable phase of COPD were
searched in PubMed (1990-December 2010), in Eng-
lish and using Chinese National Knowledge Infra-
structure (CNKI, 1990-December 2010), Chinese Bio-
medical Database (1990-December 2010), Wang-
fang Database (1990-December 2010), and Weipu
(VIP) Database in Chinese. The quality assessment
and data extraction for RCTs were conducted by
two reviewers independently. Jadad scale and allo-
cation concealment were used to assess the quality
of the included studies, and meta-analyses were
conducted with the Collaboration's Revman 5.0
software.
RESULTS: Seventeen RCTs or quasi-RCTs involving
1269 patients were included. The methodological
quality was poor in all trials except one trial (Jadad
score=4). In the meta-analysis, TCM-WM treatment
was significantly superior to WM treatment in cure
rate [OR=3.82, 95%CI (2.45, 5.95)], and the effective
rate between TCM treatment and placebo also had
significant difference [OR=4.31, 95%CI (2.35, 7.91)].
Moreover, pulmonary function of the patients in
TCM-WM group and TCM group was significantly
improved [forced vital capacity (FVC), P=0.01, quali-
ty of life, P<0.001].
CONCLUSION: The experience in TCM-WM treat-
ment of COPD in stable phase was encouraging.
The current evidence shows that TCM-WM treat-
ment might be more efficient in effective rate, qual-
ity of life, and FVC than WM treatment alone. But
for forced expiratory volume in one second (FEV1)
and FEV1/FVC, no matter TCM-WM treatment com-
pared with WM treatment alone or TCM treatment
compared with placebo, there was no significant
difference, with no obvious adverse reactions. Due
to the low methodological quality of trials includ-
ed, more RCTs of high quality in large scale are re-
quired.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD), char-
acterized by progressive expiratory aiflow limitation, is
a major cause of chronic morbidity and mortality
worldwide.1 According to the World Health Organiza-
tion (WHO),2 the total number of deaths from COPD
in the world are projected to increase by 30% in the
next 10 years; by 2030, COPD would become the
fourth leading cause of death worldwide. Among all
the major chronic diseases, COPD is the only disease
that shows a rising mortality. These increases are main-
ly linked to the epidemic of tobacco exposure and the
indoor and outdoor air pollution in Asian countries.
The goals of treatment for COPD are to control acute
attack and improve pulmonary function, prevent seri-
ous long-term consequences of pulmonary heart dis-
ease and respiratory failure. Treatment for patients in
stable phase is very important to the fate of COPD. In
China, Traditional Chinese Medicine (TCM), as an
auxiliary therapy to Western Medicine (WM), was ex-
tensively employed for the treatment of stable COPD.
In our clinic, it was found that patients with COPD
had damage to the spleen functions. Accordingly, Jian-
pi prescription was chosen as it strengthens body resis-
tance through strengthening the spleen. So, Jianpi ther-
apy became one of the main methods in TCM for sta-
ble COPD. In parallel with the Jianpi therapy, a series
of studies were conducted to evaluate the effectiveness
of Jianpi auxiliary therapy in WM, Jianpi therapy ver-
sus WM alone and placebo. To date, some of the ran-
domized controlled trials have investigated the benefi-
cial effects of Jianpi auxiliary therapy in WM and the
Jianpi therapy alone in improvement of the clinical
symptoms, and the pulmonary function in stable
COPD. However, the results were inconsistent due to
different in study design and outcome measures. So,
we conducted a meta-analysis using updated literature
searches to asses the effects and to determine whether
Jianpi auxiliary therapy in WM or Jianpi therapy alone
were more efficacious than WM alone/placebo in im-
proving the clinical symptoms, increasing lung func-
tion, increasing quality of life, and improving the other
clinical outcomes.
METHODS
Truly or quasi-randomized controlled trials (RCTs) of
TCM for COPD were included, regardless of whether
the intervention was blinded to the patients, clinicians
or researchers after randomization was done. Trials
compared WM with TCM in the control arm were al-
so included. Trials using animals or their processed
products were excluded. All eligible literature was in-
cluded regardless of language. In accordance with our
main purpose outlined above, the trials that used TCM
in both the treatment and control groups were exclud-
ed, as well as the trials that did not report diagnostic
criteria. Figure 1 shows the flowchart of the present sys-
tematic review.
Literature search
Literature search was performed using PubMed
(1990-December 2010), in English by 2 reviewers
(Juhong Zhang and Zhen Gao) and using Chinese Na-
tional Knowledge Infrastructure (CNKI) (1990-De-
cember 2010), Chinese Biomedical Database (1990-
December 2010), Wangfang Database (1990-Decem-
ber 2010), and VIP Database in Chinese by 2 review-
ers (Juhong Zhang and Zhen Gao). Key words used in
the search were Chronic Obstructive Lung Disease,
COPD, Jianpi (means invigorating the spleen,
strengthening the spleen, or nourishing the spleen).
Various combinations of the search terms were used de-
pending on the database searched. The type of publica-
tion searched was clinical study. Two reviewers for the
English literature and Chinese literature worked inde-
pendently for inclusion. Any disagreements were re-
solved through discussion.
Data extraction
For the included studies, data were extracted by 2 re-
viewers (Juhong Zhang and Zhen Gao). Once complet-
ed, any disagreements on data extraction and study
evaluation were resolved through discussion. The data
included study design, patient characteristics, and med-
ication use.
Data analysis
Data were analyzed using Revman 5.0 downloaded
from the website of Cochrane collaboration. Meta-anal-
ysis was performed for the data. The dichotomous data
were expressed as odds ratio (OR) with corresponding
95% confidence interval (95%CI). For continuous da-
ta, standardized mean difference (SMD) and 95% CI
were calculated. Heterogeneity was tested by χ2 test.
The comparison (Figure 2-4) was split into two parts:
first comparing TCM with WM, and second compar-
ing TCM plus WM to WM alone. Although the con-
stituents of the compounds were different in each in-
vestigation, the whole compounds of TCM should
have the following benefits of nourishing Qi and kid-
ney, strengthening spleen and lung. A process was de-
signed to combine across studies to perform a me-
ta-analysis. If the main effects of the whole compound
in the studies were similar, the data was combined. The
fixed-effect mode was used to combine dichotomous
data if homogeneity was found. If heterogeneity was
found, the random effect mode was alternatively used.
To make the meta-analysis more clinically meaningful,
publication bias would be examined by the funnel plot.
RESULTS
Identified studies and characteristics
The English- and Chinese-language literature search
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yielded a total of 263 published studies, of which the
abstracts were reviewed, and then 188 studies were ex-
cluded because lack of the controls. The 75 RCTs that
were potentially relevant were further reviewed, of
which 56 were excluded, 29 because of the duplicate
publications, 12 because of comparing between differ-
ent Chinese medicines, 15 because of pseudorandom
and nonrandomized. Finally, 19 RCTs or quasi-RCTs
that met the inclusion criteria were included. A total of
1587 subjects in 19 RCTs with a diagnosis of stable
COPD were included (Table 1). However, only 1496
subjects in 17 RCTs were included in Meta analysis (2
RCTs were excluded because of poor quality, but in-
cluded in the systematic review) (Figure 1).
Quality assessment
Table 2 shows the methodologic qualities of trials. Of
the 19 RCTs,3-21 most of them did not provide ade-
quate information about the methods of blinding, and
none of them provide adequate information about
ITT. According to the Jadad scoring method, of the 19
RCTs, 1 study16 scored 4 points, 4 studies6-8,18 scored 3
points, 5 studies scored 2 points,4,5,13,17,21 and the remain-
ing 9 studies3,9-15,19,20 each scored 1 point. According to
the Allocation concealment, 4 RCTs8,16,18,21 got B, 14
RCTs 3-7,10-15,17,19,20 got C, and 19got D (poor quality).
Meta-analysis
In meta-analysis, we only analysed the ending indexes
which had no significant heterogeneity. 12 studies com-
pared TCM with WM were included in meta-analysis.
Since they nourished the spleen, we combined data
across 12 studies. Notably, the meta-analysis of
high-quality trials demonstrated that there was signifi-
cant difference in cure rate between TCM-WM group
and WM group [total OR=3.59, 95%CI (2.33, 5.52)]
without heterogeneity (χ2=5.52, df =8). The significant
difference was also found in cure rate between TCM
group and placebo group [total OR=2.81, 95% CI
(1.41, 5.59)] without heterogeneity (χ2=1.66, df=2)
Figure 1 Flow chart with literature search results
RCT: randomized controlled trial; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; QL: quality of life; TCM:
Traditional Chinese Medicine;WM:Western Medicine.
RCTs withdrawn because of poor quality: (n=2)
Potentially relevant RCTs screened for retrieval (n=263)
RCTs exclued: did not meet the criteria (n=188)
RCTs retrieved for detailed evaluation (n=75)
1. Puplicated RCTs (n=29);
2. RCTs comparing between different Chinese medicines were excluded
(n=12)
Potentially appropriate RCTs to be potentially appropriate
RCTs to be included in meta-analysis (n=19)
RCTs with usable information on:
effective rate (n=14); FEV1 (n=12);
FVC (n=5); FEV1/FVC (n=9); QL (n=4);
6-min walking test (n=4)
TCM-WM group vs WM group (n=12) TCM group vs placebo group (n=5)
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(Figure 2).
We also analyzed the pulmonary function and quality
of life (QL) in RCTs. Three studies compared the FVC
between TCM-WM group and WM group [SMD=
0.36, 95%CI (0.08, 0.36), P=0.01] without heteroge-
neity (χ2=1.57, df=2), and two studies compared the
QL between the two groups [SMD=-0.82, 95% CI
(-1.21, -0.43), P<0.0001] (Figure 3).
Between TCM group and placebo group, only FVC
was significantly improved in TCM group [total SMD=
0.54, 95% CI (0.27, 0.81), P<0.0001]. However, no
significant difference was found in other parameters of
pulmonary function (FEV1and FEV1/FVC) between
the two groups (P>0.05) (Figure 4).
Because of significant heterogeneity, some parameters
of the trials were not included in meta-analysis. Table 3
shows the outcome end-points which were not includ-
ed in meta-analysis but reported in RCTs.
The funnel plot (Figure 5) shows that there was signifi-
cant publication bias in effective rate. With fewer than
five trials to compare, we did not examine publication
bias of the other ending indexes in meta-analysis.
DISCUSSION
To date, using the bronchodilator and inhaled steroids
for patients with COPD remains controversial. Bron-
chodilator has a modest effect on improving lung func-
tion. Steroids inhaled are given only for the patients
with more severe airway obstruction and frequent exac-
Table 1 The characteristics of trials
Trail
TCM-WM vs WM
Feng XZ 200615
Liu DP 200714
Wang S 200513
Wang JR 201012
Sun Sh 201011
Shan LY 200710
Song C 20093
Han H 20094
Liang AL 20095
Fu ZY 20086
Lin XL 20108
Qi WP 20097
Wu YQ 2007a9
TCM vs placebo
Ke XX 201016
Li YL 200717
Lin L 200318
Zhang MX 200619
Tang CY 200420
Liu H 200621
Participants
T/C
36/33
32/30
20/20
45/45
38/38
28/27
30/30
29/29
30/30
30/30
30/30
30/30
63/59
131/60
30/30
30/30
24/22
30/30
120/60
Range of age
(year)
T/C
unclear
62/53
59±8/61±8
69/68
55±11/55±11
67±6/67±5
66±8/64±10
69±5/69±7
71±8/71±9
70±5/68±6
71±6/70±6
70±7/74±7
62/62
69±8/68±8
69±8/71±6
62/60
67±7/68±5
70/70
67±10/66±10
Duration
(week)
30
12
8
12
12
24
4
12
12
Unclear
12
8
12
8
8
8
24
8
8
Intervention measure
Treatment
Oral aminophylline +Jianpi
and Bufei
Oral compound ipratropium
bromide+Bushen, Jianpi and
Huayu
Oral ambroxol
hydrochloride+inhal
salbutamol+Yifei and Jianpi
Inhal salbutamol+Jianpi
Oral theophylline+inhal
salbutamol + Jianpi Hutan
Oral theophylline+Jianpi
Inhal salbutamoloral +oral
Bufei, Jianpi and Yishen
Oral theophylline+oral
Jianpi and Yifei
Oral salmeterol+
aminophylline +oral Jianpi
and Yifei
Oral Jianpi and Yifei+
ambroxol hydrochloride
oral Jianpi Yifei+Ambroxol
Hydrochloride
Oral aminophylline +Yiqi
and Jianpi
Oral erythromycin+Yiqi and
Jianpi
Oral Jianpi and Yifei
Oral Gubenshengjin
Oral Jianpi and Yifei
Oral Jianpi and Yifei
Oral Jianpi and Yifei
Gushen Dingchuan
Control
Oral aminophylline
Oral compound
ipratropium
bromide
Oral ambroxol
hydrochloride+
inhal salbutamol
Inhal salbutamol
Oral theophylline+
inhal salbutamol
Oral theophylline
Inhal
salbutamoloral
Oral theophylline
Oral salmeterol+
aminophyl line
Ambroxol
hydrochloride
Ambroxol
Hydrochloride
Oral aminophylline
Oral erythromycin
Placebo
Blank
Blank
Blank
Placebo
Blank
Ending
index
①②③
①②③
②③
①
①②③⑥
①
①②③④⑤①②③⑥
①②③⑤
①②④⑥
①⑥
②⑤
②③⑥
②③⑤
①②③④⑥
①②⑥
①②③④
①④
②③⑥
Notes: T: treatment; C: control; TCM: Traditional Chinese Medicine; WM: Western Medicine; T/C: treatment/control.① total effective
rate,② FEV1: forced expiratory volume in one second;③ FEV1/FVC: forced expiratory volume in one second/ forced vital capacity;④
QL: quality of life;⑤ 6-MWT :6-minute walking test;⑥ FVC :forced vital capacity. aNot included in meta-analysis.
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erbations.1 Treatment with the combined use of in-
haled steroids and long-acting bronchodilators im-
proves the lung function, clinical symptoms and quali-
ty of life as compared with the placebo treatment, but
the reports on its effects compared with its mono-com-
ponents are conflicting.22,23 The combination therapy
reduces sputum neutrophil percentage, sputum eosino-
phil counts, and biopsy CD8 lymphocytes in stable
COPD.24 Despite the modest beneficial effects, with-
drawal of inhaled steroids may result in deterioration
to lung function. So, TCM is an ideal therapeutic
method to make up this shortcoming. Many trials
show that TCM can improve patients' pulmonary func-
tion and quality of life.
In the present study, we summarized the results of the
findings from 17 RCTs using meta-analysis; 2 RCTs
were included in the systematic review, but they were
excluded from meta-analysis because of poor quality.
There is no convincing evidence to support that Jianpi
auxiliary therapy as well as WM/Jianpi therapy could
significantly improve effective rate and pulmonary
function. However, the treatment of COPD with a com-
bination of Chinese and Western medicine could im-
prove effective rate, pulmonary function and quality of
life, as compared with the findings from Zhou et al's
study.25
The traditional Western Medicine treatment of COPD
are using bronchodilators and anti-inflammatory. Gen-
erally, we should not consider that in the treatment of
COPD, WM is effective or not. And we can evaluate
the short-term or long-term efficacy of bronchodilator
asthma medications or anti-inflammatory treatment
for COPD. One systematic review about TCM treat-
ment of COPD in stable phase has been reported,25
but the treatment is TCM not the Jianpi therapy only.
If we don't make this systematic review, those who
don't know much about TCM may say TCM is a
method that may be useful for COPD. But TCM is
not a method, just like WM, it include many different
methods, some methods may be useful for COPD, and
some may not. So, if you put all the methods together
to do the evaluation, it may be hard to evaluate the ef-
fect of TCM.
In TCM, Lung belongs to "metal", and Spleen belongs
to "soil". TCM holds that "soil can transform into met-
al". That is to say, "soil (spleen)" is the mother of "met-
al (lung)", and the "mother organ (spleen)" can supply
some essence to "son organ (lung)", just like the land
can provide nutrients to plants. If the "son organ (lung)
" is becoming weak, it will overuse the essence that the
"mother organ (spleen)" supply; and in order to meet
the "son organ (lung)"'s need, the "mother organ
(spleen)" will sooner or later become weak too, then it
can not give enough essence, so the "son organ (lung)"
will become weaker and weaker. It is also considered in
TCM that the spleen is the basis of acquired constitu-
tion. Above all, Jianpi therapy is one of the important
methods of TCM for treating chronic lung diseases,
but whether Jianpi therapy is useful or not for treating
COPD in sable phase is still lack of systematic evalua-
tion. Therefore, we conducted this systematic review to
evaluate Jianpi therapy of TCM for treating COPD in
stable phase.
In this study, the analyses provided clear evidence to
support the notion that the TCM-WM treatments
might be more efficient in effective rate, quality of life,
FVC, than WM treatment alone. But for FEV1 and
FEV1/FVC, no matter TCM-WM treatment com-
pared with WM treatment alone or TCM treatments
compared with placebo, there was no significant differ-
ence. The present results were partly consistent with
the results from a previously published meta-analysis.25
Our results suggest that the adjunctive treatment of
TCM could significantly improve the patients' quality
of life, but this maybe just change the patients' feeling,
not really improve the patients' pulmonary function.
Quality of life was improved significantly in
TCM-WM group (P<0.0001), but no significant differ-
ence was found in other parameters of pulmonary func-
tion (FEV1 and FEV1/FVC) between the two groups
(P>0.05). There was no doubt thatTCM can significant-
ly improve effective rate, how well such effects could be
translated into clinical outcomes were unknown.This as-
pect of benefits warrants further investigation.
The results of this study should be considered within
Table 2 The methodological quality of trials
Trial
TCM-WM vs WM
Feng XZ 200615
Liu DP 200714
Wang S 200513
Wang JR 201012
Sun SH 201011
Shan LY 200710
Sun C 20093
Han H 20094
Liang AL 20095
Fu ZY 20086
Lin XL 20108
Qi WP 20097
Wu YQ 20079
TCM vs placebo
Ke XX 201016
Li YL 200717
Li L 200318
Zhang MX 200619
Tang CY 200420
Li H 200621
Follow-up
duration
(month)
Unclear
Unclear
Unclear
12
3
Unclear
Unclear
Unclear
3
Unclear
Unclear
Unclear
Unclear
4
Unclear
Unclear
Unclear
Unclear
Unclear
Jadad
score
1
1
2
1
1
1
1
2
2
3
3
3
1
4
2
3
1
1
2
Allocation
concealment
C
C
C
C
C
C
C
C
C
C
B
C
D
B
C
B
C
C
B
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Trial
TCM-WM vs WM
Feng XZ 200615
Liu DP 200714
Wang S 200513
Wang JR 201012
Sun SH 201011
Shan LY 200710
Song C 20093
Han H 20094
Liang AL 20095
Fu ZY 20086
Lin XL 20108
Qi WP 20097
TCM vs Placebo
Ke XX 201016
Li YL 200717
Liu H 200621
Zhang MX 200619
Tang CY 200420
Intervention measure
Treatment
Oral aminophylline +Jianpi and
Bufei
Oral compound ipratropium
bromide+Bushen, Jianpi and
Huayu
Oral ambroxol hydrochloride+
inhal salbutamol+Yifei and
Jianpi
Inhal salbutamol+Jianpi
Oral theophylline+inhal
salbutamol + Jianpi and Huatan
Oral theophylline+Jianpi
Inhal salbutamoloral +oral
Bufei, Jianpi and Yishen
Oral theophylline+oral Jianpi
and Yifei
Oral salmeterol+aminophylline
+oral Jianpi and Yifei
Oral Jianpi and Yifei+ambroxol
hydrochloride
Oral Jianpi and Yifei+ambroxol
hydrochloride
Oral aminophylline +Yiqi and
Jianpi
Oral Jianpi and Yifei
Oral Gubenshengjin
Gushen Dingchuan
Oral Jianpi and Yifei
Oral Jianpi and Yifei
Control
Oral aminophylline
Oral compound
ipratropium bromide
Oral ambroxol
hydrochloride+inhal
salbutamol
Inhal salbutamol
Oral theophylline+
inhal salbutamol
Oral theophylline
Inhal salbutamoloral
Oral theophylline
Oral salmetero l+
aminophylline
ambroxol
hydrochloride
Ambroxol
hydrochloride
Oral aminophylline
Placebo
Blank
Blank
Blank
Placebo
Significance of Ending indexes (P)a
FEV1
<0.05
>0.05
>0.05
-
-
-
-
<0.05
>0.05
>0.05
-
>0.05
>0.05
>0.05
<0.05
<0.05
-
FEV1/FVC
<0.05
>0.05
>0.05
-
-
-
-
>0.05
>0.05
-
-
-
-
>0.05
-
>0.05
>0.05
6-MWT
-
-
-
-
-
-
<0.05
-
<0.05
-
<0.05
-
<0.05
-
-
-
-
Table 3 The outcome end-points which were not included in mata-analysis reported in RCTs
Notes FEV1: forced expiratory volume in one second; FVC: forced vital capacity; 6-MWT: 6-min walking test; TCM: Traditional Chinese
Medicine; WM: Western Medicine. aCompared in parameters of pre-and post-treatment between the groups.
Figure 2 Meta-analysis for comparison of effective rate between TCM-WM group andWM group
TCM: Traditional Chinese Medicine;WM:Western Medicine
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the context of limitations. First, most of the 17 clinical
studies had low methodological quality according to
the Jadad scores. Second, there were only 2 studies that
reported the full three basic index of pulmonary func-
Figure 3 Meta-analysis for comparison of pulmonary function and QL parameters between TCM-WM group andWM group
QL: quality of life; TCM: Traditional Chinese Medicine;WM:Western Medicine
Figure 4 Meta-analysis for comparison of pulmonary function parameters between TCM group and placebo group
TCM: Traditional Chinese Medicine.
Figure 5 Funnel plot of effective rate
TCM: Traditional Chinese Medicine;WM:Western Medicine.
TCM-WM vsWM TCM vs Placebo
0.02 0.1 1 10 50
OR
SE (Log[OR])0
0.5
1
1.5
2
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tion, and no RCT report the outcomes of high-resolu-
tion RCT. Third, the variation in treatment regimens,
particularly the wide range of TCM in dose, certain
herbs, route of administration, and duration of thera-
py, became a major obstacle to a clear interpretation of
the results. Last, we examine the publication bias with
a funnel plot, publication bias may exist in trials.
The experience in TCM-WM treatment of COPD in
stable phase was encouraging. The current evidence
shows that the integrated traditional and Western Med-
icine tends to relieve the symptoms and improve quali-
ty of life for patients with stable COPD without obvi-
ous adverse reactions. Due to the low methodological
quality of trials included, more RCTs of high quality in
large scale are required.
REFERENCES
1 Fabbri LM, Hurd SS. Global Strategy for the Diagnosis,
Management and Prevention of COPD: 2003 update. Eur
Respir J 2003; 22(1): 1-2.
2 World Health Organization. World health report 2002: re-
ducing risks, promoting healthy life. Available from URL:
www.who.int/whr/2002. Accessed December 21, 2007.
3 Song C. Clinical observation on BufeiJianpiYishen decoc-
tion for treatment of COPD and mechanism study on reg-
ulating TlymPhocyte immunologic function. Chengdu
Zhong Yi Yao Da Xue 2009; 21-30.
4 Han H. The Research on Curative Effect and Influence of
Transforming Growth Factor-β1 of Chronic obstructive
Pulmonary Disease with Deficiency of both the Lung and
Spleen in Stab1e Phase by Feikangkeli. Guangzhou Zhong
Yi Yao Da Xue 2009; 20-25.
5 Liang AL. The Effect of spleen-transporting kidney-boost-
ing lung-supplementing methods in improving stable
phase of COPD patients life quality. Beijing Zhong Yi Yao
Da Xue 2009; 43-59.
6 Fu ZY. Study on efficacy of COPD with the invigorating
spleen, Eliminating phlegm and activating blood circula-
tion therapy, and its effect on pulmonary function, quality
of life. Guangzhou Zhong Yi Yao Da Xue 2008; 21-27.
7 Qi WP. Effect of supplementing Qi to invigorate the
spleen herbs on exercise endurance in patients with stable
chronic obstructive pulmonary disease. Zhejiang Zhong Yi
Yao Da Xue 2009; 2-5.
8 Lin XL. The research on curative effect and influence of
respiratory muscle fatigue of chronic obstructive pulmo-
nary disease with deficiency of both lung and spleen in sta-
ble phase by tonifying lung and spleen. Guangzhou
Zhong Yi Yao Da Xue 2010; 30-35.
9 Wu YQ, Huang ZA. An observation of Macrolides plus
Liujunzitang for COPD in stable phase. Hua Xia Yi Xue
2007; 20(6): 1213-1215.
10 Shan LY, Liu XH, Zhong LH. A clinical observation on
the effect of Peitu shengjin method for chronic obstructive
pulmonary disease in stable phase. Hubei Zhong Yi Za
Zhi 2007; 29(4): 26-27.
11 Sun S. Clinical observation on chronic obstructive pulmo-
nary disease treated with method of invigorating spleen to
remove phlegm. Zhong Guo Zhong Yi Ji Chu Yi Xue Za
Zhi 2010; 16(2): 143-144.
12 Wang JR. Clinical study in 45 cases of chronic obstructive
pulmonary disease treated with Jianpi Yifei method.
Zhong Guo Shi Yong Yi Yao 2010; 5(10): 143.
13 Wang S, Ji HY, Zhang NZ, et al. Effect of Jianpi recipe
on inflammatory cells, levels of interleukin-8 and tumor
necrosis factor-α in sputum from patients with chronic ob-
structive pulmonary disease. Zhong Guo Zhong Xi Yi Jie
He Za Zhi 2005; 25(2): 111-113.
14 Liu DP, Hong HJ. A Clinical observation on the effect of
Jianpi Huayu for chronic obstructive pulmonary disease in
stable phase. Zhong Guo Zhong Yi Ji Zheng 2007; 16(2):
152, 197.
15 Feng XZ, Yao HQ. Clinical study in 36 cases of chronic
obstructive pulmonary disease in stable phase treated with
Jianpi Bufei plus Western Medicine. Qinghai Yi Yao Za
Zhi 2006; 36(9): 82-83.
16 Ke XX. Study on clinical application of lung-spleen corre-
lation theory in the stable phase of chronic obstructive pul-
monary disease. Guangzhou Zhong Yi Yao Da Xue 2010;
9-40.
17 Li YL. The effect of the measure of strengthening spleen
and nourishing kidney for treating malnutrition caused by
COPD disease. Guangzhou Zhong Yi Yao Da Xue 2007;
11-19.
18 Lin L, Tang CY, Xu YJ. Clinical observation of
"spleen-lung nourishing granule" in treating respiratory
muscle fatigue of stable chronic obstructive pulmonary dis-
ease. Shanghai Zhong Yi Za Zhi 2003; 37(11): 10-12.
19 Zhang MX. A clinical observation of spleen-lung nourish-
ing and kidney-boosting granule for chronic obstructive
pulmonary disease in stable phase. Zhong Guo Zhong Yi
Yao Xin Xi Za Zhi 2006; 13(7): 64-65.
20 Tang CY, Lin L, Xu YJ. The clinical research into the ef-
fect of the backing up earth to generate metal on life quali-
ty in COPD patients in stable phase. Fujian Zhong Yi Yao
2004; 35(5): 1-4.
21 Liu H, Cheng YF, Li QY, Gao TL. The effects of Wensh-
en Naqi,Jianpi Lishui on lung function for chronic ob-
structive pulmonary disease in stable phase patients.
Zhong Guo Zhong Yi Ji Zheng 2006; 15(2): 116-117.
22 Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined
use of corticosteroid and long acting beta-agonist in one
inhaler for chronic obstructive pulmonary disease. Co-
chrane Database Syst Rev Published Online: 20 JAN
2010, Assessed as up-to-date: 1 AUG 2007. Available
from URL: http://onlinelibrary.wiley.com/doi/10.1002/
14651858.CD003794.pub3/full.
23 Calverley PMA, Anderson JA, Celli B, et al. Salmeterol
and fluticasone propionate and survival in chronic obstruc-
tive pulmonary disease. N Engl J Med 2007; 356(8):
775-789.
24 Barnes NC, Qiu YS, Pavord ID, et al. Antiinflammatory
effects of salmeterol/fluticasone propionate in chronic ob-
structive lung disease. Am J Respir Crit Care Med 2006;
173(7): 736-743.
25 Zhou W, Zhong YQ, Yang HM, et al. Traditional Chinese
Medicine in the treatment of chronic obstructive pulmo-
nary disease in stable stage: a systematic review of random-
ized controlled trials. Zhong Guo Xun Zheng Yi Xue Za
Zhi 2009; 9(3): 311-318.
8
